GlassScriptPhysician profile
Jenna E Byrne
NPI 1871190942
$6,821.28
in general payments reported to CMS, 2019-2025
26 companies · $849 in 2025
The $849 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,496 · 2023: $1,822 · 2024: $1,655 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,126 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,126.43 |
| Education | $199.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $816.84 | 2022-2025 | Ilumya, Blu-U, Odomzo |
| Abbvie INC. | $778.49 | 2022-2024 | |
| Genzyme Corporation | $729.87 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $719.89 | 2022-2025 | Dupixent |
| Journey Medical Corporation | $536.30 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $521.22 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $426.66 | 2022-2023 | Adbry |
| Lilly USA, LLC | $377.94 | 2022-2024 | Taltz, Olumiant |
| Dermavant Sciences, INC. | $352.56 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $286.21 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $206.80 | 2022-2024 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $196.68 | 2022-2024 | Cabtreo, Siliq, Arazlo |
| Medimetriks Pharmaceuticals, INC. | $114.03 | 2023-2024 | Clindacin Etz, Neuac |
| Almirall LLC | $107.05 | 2022-2025 | Seysara |
| Janssen Scientific Affairs, LLC | $100.98 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100.71 | 2023-2025 | Otezla, Enbrel, Otezla |
| Ucb, INC. | $89.72 | 2022-2025 | Bimzelx |
| Pfizer INC. | $82.37 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $66.99 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.86 | 2022-2023 | Spevigo |
| Galderma Laboratories, L.P. | $49.80 | 2024-2025 | Nemluvio |
| Helsinn Therapeutics (U.S.), INC. | $30.06 | 2022-2023 | Valchlor |
| Astrazeneca Pharmaceuticals LP | $22.34 | 2022 | |
| Incyte Corporation | $19.61 | 2022 | |
| Kyowa Kirin, INC. | $16.33 | 2022 | |
| Biofrontera INC. | $13.97 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Byrne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.